Case studies in severe psoriasis: A clinical strategy

Journal of Dermatological Treatment

Volumn 14, Issue SUPPL. 2, 2003, Pages 26-46

  Lebwohl, Mark ^a   Menter, Alan ^b   Koo, John ^c   Feldman, Steven R ^d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Health related quality of life; Moderate to severe psoriasis; Treatment algorithms

Indexed keywords

ALEFACEPT; ANTIMALARIAL AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIPOTRIOL; CORTICOSTEROID; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EFALIZUMAB; ETANERCEPT; ETRETIN; HYDROXYUREA; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LITHIUM; METHOTREXATE; METHOXSALEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; TACROLIMUS; TAZAROTENE; TIOGUANINE; TRIAMCINOLONE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR;

ALGORITHM; ALOPECIA; ARTHRITIS; BONE MARROW TOXICITY; CHEILITIS; CHRONIC LUNG DISEASE; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; COST; DEPRESSION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOXICITY; HERPES ZOSTER; HUMAN; HYPERLIPIDEMIA; HYPERSENSITIVITY REACTION; IMMUNOSUPPRESSIVE TREATMENT; LEG ULCER; LEUKOPENIA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TOXICITY; LYMPHOCYTOPENIA; NEPHROTOXICITY; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PUVA; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SKIN CANCER; TERATOGENICITY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0344010474     PISSN: 09546634     EISSN: None     Source Type: Journal    
DOI: 10.1080/738528791     Document Type: Review

References (49)

1. National Psoriasis Foundation: Resources: Statistics. Available at: http://www.psoriasis.org/resources/statistics/. Accessed February 18, 2003.
2. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T, The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol (2001) 137(3):280-4.
3. van de Kerkhof PC, Clinical Features. In: Van de Kerkhof PC, ed. Textbook of Psoriasis. Oxford: Blackwell Science Ltd, 1999: 3-29.
4. National Psoriasis Foundation: Facts: Psoriatic Arthritis. Available at: http://www.psoriasis.org/facts/psa/. Accessed June 15, 2003.
5. National Psoriasis Foundation: Facts: Psoriasis. Available at: http.//www.psoriasis.org/facts/psoriasis/. Accessed February 18, 2003.
6. Rapp SR, Feldman SR, Exum ML, Fleischer AB, Jr, Reboussin DM, Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol (1999) 41(3 Pt 1): 401-7.
7. Lebwohl MG, Feldman SR, Koo JY, Menter MA, Psoriasis: Treatment Options and Patient Management: National Psoriasis Foundation Approved Education Partnership. Supported by an educational grant from Roche Laboratories Inc., 2002.
8. Lebwohl M, Ali S, Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol (2001) 45(5): 649-61; quiz 662-4.
9. Menter MA, See JA, Amend WJ et al, Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7-9, 1994. J Am Acad Dermatol (1996) 34(2 Pt 1): 315-21.
10. Weinstein GD, White GM, An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol (1993) 28(3): 454-9.
11. Koo J, Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results. J Am Acad Dermatol (1999) 41(3 Pt 2): S25-8.
12. Koo JYM, How and why to employ sequential therapy for psoriasis. Skin and Aging (2000) Suppl: 16-21.
13. Stern RS, Laird N, The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study. Cancer (1994) 73(11): 2759-64.
14. Stern RS, Nichols KT, Vakeva LH, Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. N Engl J Med (1997) 336(15): 1041-5.
15. Lindelof B, Sigurgeirsson B, Tegner E et al, PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol (1999) 141: 108-12.
16. Paul CF, Ho VC, McGeown C et al, Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol. (2003) 120(2): 211-16.
17. Weinstein GD, Krueger JG, An overview of psoriasis. In: Weinstein GD, Gottlieb AB, eds. Therapy of Moderate-to-Severe Psoriasis. Portland. OR: National Psoriasis Foundation, 1993: 1-22.
18. Sege-Peterson K, Winchester R, Psoriatic Arthritis. In: Freedberg I, Eisen A, Wolff K, et al, eds. Fitzpatrick's Dermatology in General Medicine. Vol 2. New York: McGraw-Hill, Inc., 1999: 495-521.
19. Buccheri L, Katchen BR, Karter AJ, Cohen SR, Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection. Arch Dermatol (1997) 133(6): 711-15.
20. Bavinck JN, Tieben LM, Van der Woude FJ et al, Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol (1995) 13(8): 1933-8.
21. Amevive® (alefacept) Package Insert. ©Biogen, Inc., 2003.
22. Soriatane® (acitretin) Package Insert. ©Roche Laboratories Inc., 1997-2003. Available at: www.soriatane. com. Accessed June 16, 2003.
23. Geiger JM, Efficacy of acitretin in severe psoriasis. Skin Ther Lett (2003) 8(4): 1-7.
24. Murray HE, Anhalt AW, Lessard R et al, A 12-month treatment of severe psoriasis with acitretin: results of a Canadian open multicenter study. J Am Acad Dermatol (1991) 24(4): 598-602.
25. Kragballe K, Jansen CT, Geiger JM et al, A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study. Acta Derm Venereo. (1989) 69: 35-40.
26. Lebwohl M, Drake L, Menter A et al, Consensus conference on acitretin in combination with UVB or PUVA in the treatment of psoriasis. J Am Acad Dermatol (2001) 45: 544-53.
27. Mork NJ, Kolbenstvedt A, Austad J, Efficacy and skeletal side effects of two years' acitretin treatment. Acta Derm Venereol (1992) 72(6): 445-8.
28. Vahlquist A, Long-term safety of retinoid therapy. J Am Acad Dermatol (1992) 27(6 Pt 2): S29-33.
29. Van Dooren-Greebe RJ, Lemmens JA, De Boo T, Hangx NM, Kuijpers AL, Van de Kerkhof PC, Prolonged treatment with oral retinoids in adults: no influence on the frequency and severity of spinal abnormalities. Br J Dermatol (1996) 134(1): 71-6.
30. Hohl D, Pelloni F, Sigg C, Gilardi S, Jung T, A prospective study of skeletal changes during short-term acitretin therapy. Dermatology (1992) 185(1): 23-6.
31. Berbis P, [Acitretine]. Ann Dermatol Venereol (2001) 128(6-7): 737-45.
32. Neoral® (cyclosporine) Package Insert. ©Novartis Pharmaceuticals Corporation, August 2002. Available at: www.neoral.com.
33. Tan M-H, Solganick J, Lebwohl M, A guide to systemic psoriasis treatment, retinoids. Psoriasis Forum (2000) 6: 6-7.
34. Raman GV, Campbell SK, Farrer A, Albano JD, Cook J, Modifying effects of amlodipine on cyclosporin A-induced changes in renal function in patients with psoriasis. J Hypertens Suppl (1998) 16(Suppl): S39-41.
35. Zachariae H, Long-term use of cyclosporine in dermatology [Editorial]. Arch Dermatol on CD ROM (1996): 1-5.
36. Berth-Jones J, Voorhees JJ, Consensus conference on cyclosporin A microemulsion for psoriasis, June 1996. Br J Dermatol (1996) 135(5): 775-7.
37. van den Borne BE, Landewe RB, Houkes I, Schild F et al, No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis. Arthritis Rheum (1998) 41(11): 1930-7.
38. Roenigk HH, Jr, Auerbach R, Maibach H, Weinstein G, Lebwohl M, Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol (1998) 38(3): 478-85.
39. Whiting-O'Keefe QE, Fye KH, Sack KD, Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med (1991) 90(6): 711-16.
40. Feldman SR, Hu J, Immunobiologics for Psoriasis: Psoriasis as a Chronic Immune Disease. Medscape. Available at: http://www.medscape.com/viewarticle/453361. Accessed May 13, 2003.
41. Feldman SR, Role of new biologic treatments in psoriasis. Conference Coverage. 60th Annual Meeting of the American Academy of Drematology. Available at: http://www.medscape.com/viewarticle/431183. Accessed April 18, 2002.
42. Genentech. Raptiva. Available at: http://www.biooncology.com/gene/pipeline/status/opportunistic/raptiva/. Accessed March 14, 2003.
43. Layton AM, Sheehan-Dare RA, Goodfield MJ, Cotterill JA, Hydroxyurea in the management of therapy resistant psoriasis. Br J Dermatol (1989) 121: 647-53.
44. Jones EL, Epinette WW, Hackney VC, Menendez L, Frost P, Treatment of psoriasis with oral mycophenolic acid. J Invest Dermatol (1975) 65(6): 537-42.
45. Marinari R, Fleischmajer R, Schragger AH, Rosenthal AL, Mycophenolic acid in the treatment of psoriasis: long-term administration. Arch Dermatol (1977) 113(7): 930-2.
46. Silvis NG, Levine N, Pulse dosing of thioguanine in recalcitrant psoriasis. Arch Dermatol (1999) 135: 433-7.
47. Enbrel® (etanercept) Package Insert. ©Immunex Corporation, November 1998.
48. Remicade® (infliximab) Package Insert. ©Centocor, Inc., April 2003.
49. U.S. Food and Drug Administration, Pregnancy categories. Available at http://www.fda.gov/cder/present/dia1-2001/dkennedy/sld007.htm. Accessed July 30, 2003.